{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:41:05Z","timestamp":1790516465357,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>For children with haemophilia, early initiation of prophylaxis is crucial to prevent life\u2010threatening bleeds and maintain joint health throughout life. Options for prophylaxis have recently increased from replacement therapy with standard or extended half\u2010life coagulation factor products to include other haemostasis products, such as the non\u2010replacement therapy emicizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To review key factors that determine the choice of prophylaxis in young children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Key clinical questions on the implementation of prophylaxis for haemophilia in children were identified and PubMed was searched for evidence supporting guidance on the implementation of prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results of the literature search and the practical experience of the authors were used to build consensus on when to start prophylaxis, the pros and cons of the products available to guide the choice of product, and practical aspects of starting prophylaxis to guide the choice of regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this era of increasing therapeutic choices, available information about the range of treatment options must be considered when initiating prophylaxis in young children. Parents or care givers must be sufficiently informed to allow informed shared decision making. Although plentiful data and clinical experience have been gathered on prophylaxis with clotting factor replacement therapy, its use in young children brings practical challenges, such as the need for intravenous administration. In contrast, our relatively brief experience and limited data with subcutaneously administered non\u2010replacement therapy (i.e., emicizumab) in this patient group imply that starting emicizumab prophylaxis in young children requires careful consideration, despite the more convenient route of administration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14412","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T18:48:21Z","timestamp":1632250101000},"page":"889-896","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prophylaxis in children with haemophilia in an evolving treatment landscape"],"prefix":"10.1111","volume":"27","author":[{"given":"Maria Elisa","family":"Mancuso","sequence":"first","affiliation":[{"name":"Centre for Thrombosis and Haemorrhagic Diseases IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"Thrombosis &amp; Haemostasis Unit Department of Paediatrics Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[{"name":"The National Haemophilia Centre The Amalia Biron Thrombosis Research Institute Sheba Medical Centre, Tel Hashomer Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Kavakli","sequence":"additional","affiliation":[{"name":"Department of Haematology Ege University Faculty of Medicine Children's Hospital  Bornova Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Clinical and Molecular Haemostasis University Hospital Frankfurt Goethe University  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Blatn\u00fd","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Biochemistry University Hospital Brno and Masaryk University  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology Emma Children's Hospital Amsterdam UMC University of Amsterdam  Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32722-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12938"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209619"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12726"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14844"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13461"},{"key":"e_1_2_8_9_1","first-page":"378","article-title":"Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years","volume":"17","author":"Zanon E","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08469.x"},{"key":"e_1_2_8_11_1","unstructured":"World Federation of Hemophilia World Bleeding Disorders Registry;2019. Accessed: February 4 2021.https:\/\/www.wfh.org\/en\/our\u2010work\u2010research\u2010data\/world\u2010bleeding\u2010disorders\u2010registry?"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01463.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13298"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001311"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00062-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-546127"},{"key":"e_1_2_8_18_1","article-title":"Plasma or recombinant products for hemophilia?","author":"Dunn A","journal-title":"ASH Clinical News"},{"key":"e_1_2_8_19_1","first-page":"292","article-title":"Plasma\u2010derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better","volume":"8","author":"Franchini M","year":"2010","journal-title":"Blood Transfus"},{"key":"e_1_2_8_20_1","first-page":"288","article-title":"Plasma\u2010derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma\u2010derived is better","volume":"8","author":"Mannucci PM","year":"2010","journal-title":"Blood Transfus"},{"key":"e_1_2_8_21_1","first-page":"366","article-title":"Factor VIII safety: plasma\u2010derived versus recombinant products","volume":"9","author":"Gringeri A","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13834"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13803"},{"key":"e_1_2_8_26_1","first-page":"39","article-title":"Real\u2010world analysis of dispensed international units of coagulation factor VIII and resultant expenditures for hemophilia A patients: a comparison between standard half\u2010life and extended half\u2010life products","volume":"27","author":"Chhabra A","year":"2018","journal-title":"Manag Care"},{"key":"e_1_2_8_27_1","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male C","year":"2021","journal-title":"Haematologica"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14078"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03757.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13360"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13438"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14036"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-03-0179"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1705116"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13360"},{"key":"e_1_2_8_37_1","first-page":"1","article-title":"Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa","author":"\u00c1lvarez Rom\u00e1n MT","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14300"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13013"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2548-6"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13848"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27886"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16964"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13877"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14353"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13985"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14292"},{"key":"e_1_2_8_50_1","article-title":"Emicizumab dosing in children and adults with hemophilia A: simulating a user\u2010friendly and cost\u2010efficient regimen","author":"Bukkems L","year":"2021","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_51_1","article-title":"Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect Study","author":"Liesner RJ","year":"2021","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.12.004"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457036"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15942"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15076"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15342"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13616"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24340"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30048-6"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1386096"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:49:52Z","timestamp":1692830992000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/hae.14412"],"URL":"https:\/\/doi.org\/10.1111\/hae.14412","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}